You are here: Home: CCU 3 | 2005: John
L Marshall, MD: Select publications
Select publications
Cassidy J et al. Capecitabine (X) vs
bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon
cancer (the X-ACT study): Efficacy results of a phase III
trial. Proc ASCO 2004a;Abstract
3509.
Cassidy J et al. Improved safety of
capecitabine versus bolus 5-fluorouracil/leucovorin (LV)
as adjuvant therapy for colon cancer (the X-ACT phase III
study). Proc ASCO 2004b;Abstract
219.
De Gramont A et al. Oxaliplatin/5FU/LV
in the adjuvant treatment of stage II and stage III colon
cancer: Efficacy results with a median follow-up of 4 years. Proc
ASCO GI
Cancer Symposium 2005;Abstract
167.
Giantonio B et al. High-dose bevacizumab
in combination with FOLFOX4 improves survival in patients
with previously treated advanced colorectal cancer: Results
from the Eastern Cooperative Oncology Group (ECOG) study
E3200. Proc ASCO
GI Cancer Symposium 2005;Abstract
169a.
Hochster HS et al. Bevacizumab (B)
with oxaliplatin (O)-based chemotherapy in the firstline
therapy of metastatic colorectal cancer (mCRC): Preliminary
results of the randomized “TREE-2” trial. Proc
ASCO GI Cancer Symposium 2005;Abstract
241.
Hurwitz H et al. Bevacizumab plus
irinotecan, fluorouracil, and leucovorin for metastatic
colorectal cancer. N Engl
J Med 2004;350(23):2335-42. Abstract
Kabbinavar FF et al. Bevacizumab (a
monoclonal antibody to vascular endothelial growth factor)
to prolong progression-free survival in first-line colorectal
cancer (CRC) in subjects who are not suitable candidates
for first-line CPT-11. Proc
ASCO 2004;Abstract
3516.
Meyerhardt JA et al. Systemic therapy
for colorectal cancer. New
Engl J Med 2005;352(5):476-87. No abstract available
Ravdin PM, Davis GJ. Adjuvant! a computer
program for making prognostic estimates and assessing the
value and risks of adjuvant therapy for individual colon
cancer patients. Proc
ASCO GI Cancer Symposium 2005;Abstract
291.
Rothenberg ML et al. Superiority of
oxaliplatin and fluorouracil-leucovorin compared with either
therapy alone in patients with progressive colorectal cancer
after irinotecan and fluorouracil-leucovorin: Interim results
of a phase III trial. J Clin
Oncol 2003;21(11):2059-69.
Abstract
Saltz LB et al. Interim report of
randomized phase II trial of cetuximab/bevacizumab/ irinotecan
(CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory
colorectal cancer. Proc ASCO
GI Cancer Symposium 2005;Abstract
169b.
Willett CG et al. Direct evidence
that the VEGF-specific antibody bevacizumab has antivascular
effects in human rectal cancer. Nat
Med 2004;10(2):145-7. Abstract
|
